Cristina Santoro

List of Publications by Year
in descending order

98 papers	1,425 citations	394421 19 h-index	377865 34 g-index
98 all docs	98 docs citations	98 times ranked	1623 citing authors

#	Article	IF	Citations
1	Mortality and causes of death in Italian persons with haemophilia, 1990â€“2007. Haemophilia, 2010, 16, 437-446.	2.1	145
2	Bleeding risk of surgery and its prevention in patients with inherited platelet disorders. Haematologica, 2017, 102, 1192-1203.	3.5	92
3	Validation of the ISTH/SSC bleeding assessment tool for inherited platelet disorders: A communication from the Platelet Physiology SSC. Journal of Thrombosis and Haemostasis, 2020, 18, 732-739.	3.8	64
4	Bleeding phenotype and correlation with factor XI (FXI) activity in congenital <scp>FXI</scp> deficiency: results of a retrospective study from a single centre. Haemophilia, 2015, 21, 496-501.	2.1	58
5	Immune thrombocytopenia (ITP) World Impact Survey (iWISh): Patient and physician perceptions of diagnosis, signs and symptoms, and treatment. American Journal of Hematology, 2021, 96, 188-198.	4.1	55
6	Immune thrombocytopenia (<scp>ITP</scp>) <scp>World Impact Survey</scp> (<scp>Iâ€WISh</scp>): Impact of <scp>ITP</scp> on healthâ€related quality of life. American Journal of Hematology, 2021, 96, 199-207.	4.1	54
7	Healthâ€related quality of life and burden of fatigue in patients with primary immune thrombocytopenia by phase of disease. American Journal of Hematology, 2016, 91, 995-1001.	4.1	53
8	Principles of treatment and update of recommendations for the management of haemophilia and congenital bleeding disorders in Italy. Blood Transfusion, 2014, 12, 575-98.	0.4	52
9	Acquired inhibitors of clotting factors: AICE recommendations for diagnosis and management. Blood Transfusion, 2015, 13, 498-513.	0.4	48
10	Inhibitors in Hemophilia B. Seminars in Thrombosis and Hemostasis, 2018, 44, 578-589.	2.7	47
11	A long-term study of young patients with essential thrombocythemia treated with anagrelide. Haematologica, 2004, 89, 1306-13.	3.5	44
12	Prevalence of alloâ€immunization antiâ€HLA and antiâ€integrin Î±IIbÎ²3 in Glanzmann Thromboasthenia patients. Haemophilia, 2010, 16, 805-812.	2.1	43
13	Platelet cut-off for anticoagulant therapy in thrombocytopenic patients with blood cancer and venous thromboembolism: an expert consensus. Blood Transfusion, 2019, 17, 171-180.	0.4	32
14	Spleen enlargement is a risk factor for thrombosis in essential thrombocythemia: Evaluation on 1,297 patients. American Journal of Hematology, 2016, 91, 318-321.	4.1	28
15	Effect of low or high doses of lowâ€molecularâ€weight heparin on thrombin generation and other haemostasis parameters in critically ill patients with COVIDâ€19. British Journal of Haematology, 2020, 190, e214-e218.	2.5	25
16	Eltrombopag secondâ€line therapy in adult patients with primary immune thrombocytopenia in an attempt to achieve sustained remission offâ€treatment: results of a phase II, multicentre, prospective study. British Journal of Haematology, 2021, 193, 386-396.	2.5	23
17	Pharmacokinetics of plasmaâ€derived vs. recombinant <scp>FVIII</scp> concentrates: a comparative study. Haemophilia, 2015, 21, 204-209.	2.1	22
18	Emergency management in patients with haemophilia A and inhibitors on prophylaxis with emicizumab: AICE practical guidance in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Blood Transfusion, 2020, 18, 143-151.	0.4	22

#	Article	IF	Citations
19	Tapering and discontinuation of thrombopoietin receptor agonists in immune thrombocytopenia: Real-world recommendations. Blood Reviews, 2020, 41, 100647.	5.7	20
20	Performance of recalibrated ReFacto^{Â®} laboratory standard in the measurement of FVIII plasma concentration via the chromogenic and oneâ€stage assays after infusion of recalibrated ReFacto^{Â®} (Bâ€domain deleted recombinant factor VIII). Haemophilia, 2009, 15, 779-787.	2.1	19
21	The ISTH bleeding assessment tool as predictor of bleeding events in inherited platelet disorders: Communication from the ISTH SSC Subcommittee on Platelet Physiology. Journal of Thrombosis and Haemostasis, 2021, 19, 1364-1371.	3.8	19
22	Molecular characterization of 7 patients affected by dys- or hypo-dysfibrinogenemia: Identification of a novel mutation in the fibrinogen Bbeta chain causing a gain of glycosylation. Thrombosis Research, 2015, 136, 168-174.	1.7	18
23	Clinical phenotype, fibrinogen supplementation, and health-related quality of life in patients with afibrinogenemia. Blood, 2021, 137, 3127-3136.	1.4	18
24	Von Willebrand factor with increased binding capacity is associated with reduced platelet aggregation but enhanced agglutination in COVID-19 patients: another COVID-19 paradox?. Journal of Thrombosis and Thrombolysis, 2021, 52, 105-110.	2.1	18
25	Management of patients with severe haemophilia a without inhibitors on prophylaxis with emicizumab: AICE recommendations with focus on emergency in collaboration with SIBioC, SIMEU, SIMEUP, SIPMeL and SISET. Haemophilia, 2020, 26, 937-945.	2.1	17
26	PRACTICAL RECOMMENDATIONS FOR THE MANAGEMENT OF PATIENTS WITH ITP DURING THE COVID-19 PANDEMIC. Mediterranean Journal of Hematology and Infectious Diseases, 2021, 13, e2021032.	1.3	17
27	Severe Thrombotic Complications in Congenital Afibrinogenemia: A Pathophysiological and Management Dilemma. Seminars in Thrombosis and Hemostasis, 2016, 42, 577-582.	2.7	16
28	DIRECT ORAL ANTICOAGULANTS IN PATIENTS AFFECTED BY MAJOR CONGENITAL THROMBOPHILIA. Mediterranean Journal of Hematology and Infectious Diseases, 2019, 11, e2019044.	1.3	16
29	The burden of bleeds and other clinical determinants on caregivers of children with haemophilia (the) Tj ETQq1 1 0.784314 rgBT /Ove	2.1	16
30	Successful hip arthroplasty in an adult male with severe factor XI deficiency using Hemoleven^{Â®}, a factor XI concentrate. Haemophilia, 2011, 17, 777-782.	2.1	15
31	Comorbidities in persons with haemophilia aged 60 years or more compared with ageâ€matched people from the general population. Haemophilia, 2018, 24, e6-e10.	2.1	15
32	Safety of Switching Factor VIII Products in the Era of Evolving Concentrates: Myths and Facts. Seminars in Thrombosis and Hemostasis, 2016, 42, 563-576.	2.7	14
33	<scp>TPO</scp>â€<scp>RA</scp>s in <scp>pITP</scp>: description of a case series and analysis of predictive factors for response. European Journal of Haematology, 2017, 98, 242-249.	2.2	14
34	A multicenter realâ€life study on anticoagulant treatment with direct oral anticoagulants in patients with <scp>P</scp>hâ€negative myeloproliferative neoplasms. American Journal of Hematology, 2020, 95, E329-E332.	4.1	14
35	Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. Leukemia Research, 2016, 46, 18-25.	0.8	13
36	The impact of psychosocial determinants on caregiversâ€™ burden of children with haemophilia (results) Tj ETQq0 0 0 rgBT /Overlock 1	2.1	13

#	Article	IF	Citations
37	Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE). Seminars in Thrombosis and Hemostasis, 2018, 44, 551-560.	2.7	12
38	Tailored versus Standard Dose Prophylaxis in Children with Hemophilia A. Seminars in Thrombosis and Hemostasis, 2013, 39, 711-722.	2.7	11
39	PICC-related upper deep venous thrombosis in patients with hematological malignancies. Management of anticoagulant therapy according to the platelet count. Journal of Thrombosis and Thrombolysis, 2020, 49, 426-430.	2.1	11
40	Genotypes of European and Iranian patients with type 3 von Willebrand disease enrolled in 3WINTERS-IPS. Blood Advances, 2021, 5, 2987-3001.	5.2	11
41	Role of treatment on the development of secondary malignancies in patients with essential thrombocythemia. Cancer Medicine, 2017, 6, 1233-1239.	2.8	9
42	High platelet count at diagnosis is a protective factor for thrombosis in patients with essential thrombocythemia. Thrombosis Research, 2017, 156, 168-171.	1.7	9
43	F9 missense mutations impairing factor IX activation are associated with pleiotropic plasma phenotypes. Journal of Thrombosis and Haemostasis, 2022, 20, 69-81.	3.8	9
44	Haemostasis prophylaxis using single dose desmopressin acetate and extended use epsilon aminocaproic acid for adenotonsillectomy in patients with type 1 von Willebrand disease. Haemophilia, 2012, 18, 200-204.	2.1	8
45	ACQUIRED HAEMOPHILIA A: AN INTRIGUING DISEASE. Mediterranean Journal of Hematology and Infectious Diseases, 2020, 12, e2020045.	1.3	8
46	Direct oral anticoagulants in patients with hematologic malignancies. Hematological Oncology, 2020, 38, 589-596.	1.7	8
47	Anagrelide in Essential Thrombocythemia (ET): Results from 150 patients over 25Âyears by the â€œPh1â€negative Myeloproliferative Neoplasms Latium Groupâ€. European Journal of Haematology, 2020, 105, 335-343.	2.2	8
48	Pain assessment and management in Italian Haemophilia Centres. Blood Transfusion, 2021, 19, 335-342.	0.4	8
49	Cancers in Patients with von Willebrand Disease: A Survey from the Italian Association of Haemophilia Centres. Seminars in Thrombosis and Hemostasis, 2016, 42, 036-041.	2.7	7
50	Rate and appropriateness of polypharmacy in older patients with hemophilia compared with ageâ€matched controls. Haemophilia, 2018, 24, 726-732.	2.1	7
51	Management of elderly patients with immune thrombocytopenia: Real-world evidence from 451 patients older than 60Âyears. Thrombosis Research, 2020, 185, 88-95.	1.7	7
52	Antithrombotic prophylaxis for surgery-associated venous thromboembolism risk in patients with inherited platelet disorders. The SPATA-DVT Study. Haematologica, 2020, 105, 1948-1956.	3.5	7
53	Predictors of inhibitor eradication by primary immune tolerance induction in severe haemophilia A with high responding inhibitors. Haemophilia, 2022, 28, 55-64.	2.1	7
54	Dental invasive procedures in von Willebrand disease outpatients treated with high purity FVIII/VWF complex concentrate (FanhdiÂ®): experience of a single center. Heliyon, 2020, 6, e03426.	3.2	6

#	Article	IF	Citations
55	Repeated successful use of eltrombopag in chronic primary immune thrombocytopenia: description of an intriguing case. Clinical Case Reports (discontinued), 2017, 5, 1385-1388.	0.5	5
56	BAY 81â€8973 prophylaxis and pharmacokinetics in haemophilia A: Interim results from the TAURUS study. European Journal of Haematology, 2020, 105, 164-172.	2.2	5
57	Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERSâ€IPS study. Journal of Thrombosis and Haemostasis, 2022, 20, 1106-1114.	3.8	5
58	Haemophilia management and treatment: An Italian survey on patientsâ€™, caregiversâ€™ and cliniciansâ€™ point of view. Haemophilia, 2022, 28, 254-263.	2.1	5
59	Immune thrombocytopenia management during COVIDâ€19 pandemic: An Italian monocentric experience. EJHaem, 2022, 3, 453-456.	1.0	5
60	Are ET and PV Patients Two Similar Populations As Concern Thrombotic Risk Factors?. Blood, 2015, 126, 2811-2811.	1.4	4
61	Rituximab in Previously Treated Primary Immune Thrombocytopenia Patients: Evaluation of Short- and Long-Term Efficacy and Safety. Acta Haematologica, 2014, 132, 24-29.	1.4	3
62	ABO Blood Group and Inhibitor Risk in Severe Hemophilia A Patients: A Study from the Italian Association of Hemophilia Centers. Seminars in Thrombosis and Hemostasis, 2021, 47, 084-089.	2.7	3
63	Eltrombopag treatment for severe immune thrombocytopenia during pregnancy: a case report. Blood Coagulation and Fibrinolysis, 2021, 32, 519-521.	1.0	3
64	Eltrombopag As Second Line Therapy in Adult Patients with Primary Immune Thrombocytopenia (ITP) in Attempt to Achieve Long-Term Remission. Preliminary Analysis of a Phase II, Multicenter, Prospective Study By Gimema Group (the ESTIT Study). Blood, 2018, 132, 1135-1135.	1.4	3
65	Italian experience with rVIII-single chain: a survey of patients with haemophilia A and their physicians. Journal of Thrombosis and Thrombolysis, 2022, 53, 934-944.	2.1	3
66	Current Choices and Management of Treatment in Persons with Severe Hemophilia A without Inhibitors: A Mini-Delphi Consensus. Journal of Clinical Medicine, 2022, 11, 801.	2.4	3
67	Decisional flow with a scoring system to start platelet-lowering treatment in patients with essential thrombocythemia: long-term results. International Journal of Hematology, 2009, 90, 486-491.	1.6	2
68	Prognostic factors for thrombosis-free survival and overall survival in polycythemia vera: A retrospective analysis of 623 PTS With long follow-up. Leukemia Research, 2018, 69, 18-23.	0.8	2
69	Immune tolerance induction with moroctocogâ€alpha (Refacto/Refacto AF) in a population of Italian haemophilia A patients with highâ€titre inhibitors: Data from REF.IT Registry. Haemophilia, 2019, 25, 1003-1010.	2.1	2
70	The role of an accurate diagnosis of inherited thrombocytopenia as the basis for an effective treatment. A case of MYH9 syndrome treated with a TPOâ€RA. Haemophilia, 2019, 25, e288-e290.	2.1	2
71	Clinical practice of personalized prophylaxis in hemophilia: Illustrations of experiences and benefits from two continents. Clinical Case Reports (discontinued), 2019, 7, 689-694.	0.5	2
72	Use of edoxaban for the treatment of venous thromboembolism in <scp>HIV</scp>â€infected patients. HIV Medicine, 2020, 21, e7.	2.2	2

#	Article	IF	Citations
73	Rituximab for treating inhibitors in people with inherited severe hemophilia. The Cochrane Library, 2020, 8, CD010810.	2.8	2
74	Single centre experience on Acquired Haemophilia A patients: Diagnosis, clinical management and analysis of factors predictive of response and outcome. Haemophilia, 2021, 27, e667-e674.	2.1	2
75	Acquired FXIII deficiency and AL amyloidosis: A case of a rare association. Transfusion and Apheresis Science, 2020, 59, 102903.	1.0	2
76	Secondary prophylaxis of venous thromboembolism with direct oral anticoagulants: comparison between patients with major congenital thrombophilia versus non-thrombophilic patients. Internal and Emergency Medicine, 2022, 17, 1081-1085.	2.0	2
77	Anticoagulant therapy in patients with Glanzmann's Thrombasthenia: Is it possible?. Haemophilia, 2017, 23, e531-e533.	2.1	1
78	Alloantibodies and Congenital Bleeding Disorders: New Insights in the Pathogenesis and Management. Seminars in Thrombosis and Hemostasis, 2018, 44, 505-508.	2.7	1
79	Thrombopoietin receptor agonists to control immune thrombocytopenia in patients with active lymphoma. British Journal of Haematology, 2019, 186, e217-e219.	2.5	1
80	Thrombosis History and Relationship with Low Thrombocytosis, Leukocytosis, and Jak2 V617F Mutation In A Cohort of 977 Patients with Essential Thrombocythemia (ET): Preliminary Report of the Registro Italiano Trombocitemia(RIT),. Blood, 2011, 118, 3836-3836.	1.4	1
81	Comparison of quality of life, and emotional and functional profiles in older people with and without severe haemophilia. Haemophilia, 2021, 27, e525-e529.	2.1	1
82	Application of the International Prognostic Score of Thrombosis for Essential Thrombocytemia(ET) (IPSET-Thrombosis) in a Cohort of ET Patients: Experience from Gruppo Laziale for Myeloproliferative Ph Negative Neoplasms. Blood, 2015, 126, 2821-2821.	1.4	1
83	Identification of the Profile of the Patients with Hemophilia B Eligible for Treatment with Nonacog Alfa Once-Weekly. Reports, 2020, 3, 3.	0.5	0
84	Right elbow arthropathy in a patient with severe haemophilia A. British Journal of Haematology, 2020, 190, 484-484.	2.5	0
85	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of 2001 WHO Versus 2008/2016 WHO Criteria in a Large Single-center Cohort. Clinical Lymphoma, Myeloma and Leukemia, 2021, 21, e328-e333.	0.4	0
86	A retrospective patient chart review of real-world clinical outcomes and prophylactic factor VIII consumption in Italian patients with haemophilia A switching to extended dosing intervals with rVIII SingleChain. , 2021, 41, .		0
87	A comparison of prophylaxis dosing frequency and associated clinical outcomes between rVIII-SingleChain and other rFVIII products commonly used in Italian patients with haemophilia A. Hamostaseologie, 2021, 41, .	1.9	0
88	The Platelet COUNT at Diagnosis of Essential Thrombocythemia Is a Prognostic Factor for Thrombosis-Free Survival: Retrospective Analysis on 1201 Patients. Blood, 2015, 126, 2815-2815.	1.4	0
89	Clinical and Biological Features in Patients with Ph-Negative Chronic Myeloproliferative Neoplasm Showing Different Molecular Pattern. Comparative Study in 596 Patients of the Registro Italiano Trombocitemie (RIT). Blood, 2015, 126, 4071-4071.	1.4	0
90	Health-Related Quality of Life in Patients with Primary Immune Thrombocytopenia (pITP): Investigating Differences Amongst Newly Diagnosed, Persistent and Chronic Pitp Patients. Blood, 2015, 126, 2122-2122.	1.4	0

#	Article	IF	Citations
91	Essential Thrombocythemia: A Comparison of Overall and Thrombosis Free Survival in Two Discrete Periods of the First Decade of 2000. a Retrospective Analysis. Blood, 2016, 128, 5469-5469.	1.4	0
92	Prospective Study of the Immunological Mechanisms of Immune Tolerance Induction in Severe Haemophilia a Patients with Inhibitors: Preliminary Analysis of a Multi-Center Longitudinal Study. Blood, 2018, 132, 3781-3781.	1.4	0
93	Straightforward Transition to Bay 81-8973 Prophylaxis in Patients with Hemophilia A: Prospective Real-World Data from the Taurus Non-Interventional Study Show That Number of Infusions per Week Is Maintained or Reduced. Blood, 2018, 132, 5045-5045.	1.4	0
94	Determinants of Prophylaxis Regimen Choice for Patients with Hemophilia Î‘ Switching to Bay 81-8973: Real World Findings from the Taurus Non-Interventional Study. Blood, 2018, 132, 5023-5023.	1.4	0
95	Clinical and Prognostic Features of Essential Thrombocythemia: Comparison of Who 2001 Versus Who 2008/2016 Criteria in a Large Single Center Cohort. Blood, 2018, 132, 5464-5464.	1.4	0
96	ITP World Impact Survey (I-WISh) 2.0: Further Exploration of the Impact of ITP on Patients. Blood, 2020, 136, 2-3.	1.4	0
97	(Auto)Antibody Responses Shape Memory NK Cell Pool Size and Composition. Biomedicines, 2022, 10, 625.	3.2	0
98	Factor XI deficiency and delayed hemorrhages after resection of choroid plexus papilloma: illustrative case. Journal of Neurosurgery Case Lessons, 2021, 2, .	0.3	0